Sara Teresinha Olalla Saad

List of Publications by Year
in descending order

319 papers	4,700 citations	126901 33 h-index	182417 51 g-index
321 all docs	321 docs citations	321 times ranked	7224 citing authors

#	Article	IF	Citations
1	Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia, 2014, 28, 78-87.	7.2	256
2	Probiotics modulate gut microbiota and improve insulin sensitivity in DIO mice. Journal of Nutritional Biochemistry, 2017, 50, 16-25.	4.2	193
3	An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nature Genetics, 2006, 38, 807-812.	21.4	172
4	Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis. PLoS ONE, 2012, 7, e43090.	2.5	97
5	Antitumor activities of Quercetin and Green Tea in xenografts of human leukemia HL60 cells. Scientific Reports, 2018, 8, 3459.	3.3	74
6	Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation. Haematologica, 2008, 93, 605-609.	3.5	70
7	The release of nitric oxide and superoxide anion by neutrophils and mononuclear cells from patients with sickle cell anaemia. British Journal of Haematology, 1996, 93, 333-340.	2.5	69
8	The polyphenol quercetin induces cell death in leukemia by targeting epigenetic regulators of pro-apoptotic genes. Clinical Epigenetics, 2018, 10, 139.	4.1	65
9	Prothrombin mutant, factor V Leiden, and thermolabile variant of methylenetetrahidrofolate reductase among patients with sickle cell disease in Brazil. , 1998, 59, 46-50.		57
10	Multitarget Effects of Quercetin in Leukemia. Cancer Prevention Research, 2014, 7, 1240-1250.	1.5	57
11	Pancytopenia in Untreated Patients with Graves' Disease. Thyroid, 2006, 16, 403-409.	4.5	54
12	ARHGAP10, a novel human gene coding for a potentially cytoskeletal Rho-GTPase activating protein. Biochemical and Biophysical Research Communications, 2002, 294, 579-585.	2.1	53
13	Follow-up of sickle cell disease patients with priapism treated by hydroxyurea. American Journal of Hematology, 2004, 77, 45-49.	4.1	52
14	ARHGAP21 is a RhoGAP for RhoA and RhoC with a role in proliferation and migration of prostate adenocarcinoma cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 365-374.	3.8	50
15	ARHGAP21 Protein, a New Partner of Î±-Tubulin Involved in Cell-Cell Adhesion Formation and Essential for Epithelial-Mesenchymal Transition. Journal of Biological Chemistry, 2013, 288, 2179-2189.	3.4	49
16	CXCR7 Is Highly Expressed in Acute Lymphoblastic Leukemia and Potentiates CXCR4 Response to CXCL12. PLoS ONE, 2014, 9, e85926.	2.5	49
17	Role of innate immunity-triggered pathways in the pathogenesis of Sickle Cell Disease: a meta-analysis of gene expression studies. Scientific Reports, 2015, 5, 17822.	3.3	48
18	Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients. British Journal of Haematology, 2004, 124, 547-554.	2.5	47

#	Article	IF	Citations
19	Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. Leukemia Research, 2014, 38, 1245-1251.	0.8	47
20	Human leukocyte formin: a novel protein expressed in lymphoid malignancies and associated with Akt. Biochemical and Biophysical Research Communications, 2003, 311, 365-371.	2.1	46
21	ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells. Experimental Cell Research, 2014, 324, 137-145.	2.6	46
22	Leukocyte numbers correlate with plasma levels of granulocyteâ€“macrophage colony-stimulating factor in sickle cell disease. Annals of Hematology, 2007, 86, 255-261.	1.8	45
23	Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea. American Journal of Hematology, 2004, 76, 343-347.	4.1	44
24	p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas. American Journal of Hematology, 2001, 67, 84-92.	4.1	43
25	Toll-like receptor 4 and inducible nitric oxide synthase gene polymorphisms are associated with Type 2 diabetes. Journal of Diabetes and Its Complications, 2010, 24, 192-198.	2.3	43
26	Expression of Î±-hemoglobin stabilizing protein gene during human erythropoiesis. Experimental Hematology, 2004, 32, 157-162.	0.4	42
27	Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties. European Journal of Haematology, 2006, 78, 061205033335001-???.	2.2	42
28	Effect of Cytokines and Chemokines on Sickle Neutrophil Adhesion to Fibronectin. Acta Haematologica, 2005, 113, 130-136.	1.4	41
29	FMNL1 promotes proliferation and migration of leukemia cells. Journal of Leukocyte Biology, 2013, 94, 503-512.	3.3	41
30	Detection and Possible Prognostic Relevance ofp53Gene Mutations in Diffuse Large B-cell Lymphoma. An Analysis of 51 Cases and Review of the Literature. Leukemia and Lymphoma, 2004, 45, 2071-2078.	1.3	37
31	Artemisinin-type drugs for the treatment of hematological malignancies. Cancer Chemotherapy and Pharmacology, 2021, 87, 1-22.	2.3	37
32	The CALM and CALM/AF10 interactor CATS is a marker for proliferation. Molecular Oncology, 2008, 2, 356-367.	4.6	36
33	Stathmin 1 in normal and malignant hematopoiesis. BMB Reports, 2014, 47, 660-665.	2.4	36
34	Blood group genotyping facilitates transfusion of ?-thalassemia patients. Journal of Clinical Laboratory Analysis, 2002, 16, 216-220.	2.1	35
35	Causes of incidental neutropenia in adulthood. Annals of Hematology, 2006, 85, 705-709.	1.8	35
36	Endothelial Activation by Platelets from Sickle Cell Anemia Patients. PLoS ONE, 2014, 9, e89012.	2.5	35

#	Article	IF	Citations
37	Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea. Haematologica, 2015, 100, 730-739.	3.5	34
38	BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Frontiers in Oncology, 2019, 9, 16.	2.8	34
39	ANKHD1, ankyrin repeat and KH domain containing 1, is overexpressed in acute leukemias and is associated with SHP2 in K562 cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 828-834.	3.8	33
40	Role for cAMP-protein kinase A signalling in augmented neutrophil adhesion and chemotaxis in sickle cell disease. European Journal of Haematology, 2007, 79, 330-337.	2.2	33
41	Low bone mass density is associated with hemolysis in brazilian patients with sickle cell disease. Clinics, 2011, 66, 801-805.	1.5	33
42	Participation of Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatin. Haematologica, 2011, 96, 526-533.	3.5	33
43	Red cell membrane protein abnormalities in hereditary spherocytosis in Brazil. British Journal of Haematology, 1994, 88, 295-299.	2.5	31
44	Serine peptidase inhibitor Kunitz type 2 (SPINT2) in cancer development and progression. Biomedicine and Pharmacotherapy, 2018, 101, 278-286.	5.6	31
45	High expression of FMNL1 protein in T non-Hodgkin's lymphomas. Leukemia Research, 2006, 30, 735-738.	0.8	30
46	High expression of the cGMPâ€specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils. British Journal of Haematology, 2008, 142, 836-844.	2.5	30
47	Impaired red cell deformability in iron deficient subjects. Clinical Hemorheology and Microcirculation, 2009, 43, 217-221.	1.7	30
48	Elevated plasma levels and plateletâ€associated expression of the proâ€thrombotic and proâ€inflammatory protein, <scp>T</scp>NFSF14 (LIGHT), in sickle cell disease. British Journal of Haematology, 2012, 158, 788-797.	2.5	30
49	ANKHD1 regulates cell cycle progression and proliferation in multiple myeloma cells. FEBS Letters, 2012, 586, 4311-4318.	2.8	30
50	Useful properties of undifferentiated mesenchymal stromal cells andÂadipose tissue as the source in liver-regenerative therapy studied inÂanÂanimal model of severe acute fulminant hepatitis. Cytotherapy, 2015, 17, 1052-1065.	0.7	30
51	Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes. Leukemia Research, 2006, 30, 9-16.	0.8	29
52	Chronic Liver Abnormalities in Sickle Cell Disease: A Clinicopathological Study in 70 Living Patients. Acta Haematologica, 2007, 118, 129-135.	1.4	29
53	Elevated hypercoagulability markers in hemoglobin SC disease. Haematologica, 2015, 100, 466-471.	3.5	29
54	De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes. Scientific Reports, 2017, 7, 40707.	3.3	29

#	Article	IF	Citations
55	Red blood cells microparticles are associated with hemolysis markers and may contribute to clinical events among sickle cell disease patients. Annals of Hematology, 2019, 98, 2507-2521.	1.8	29
56	Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells. Leukemia Research, 2014, 38, 251-257.	0.8	28
57	SEMA3A partially reverses VEGF effects through binding to neuropilin-1. Stem Cell Research, 2017, 22, 70-78.	0.7	28
58	BCR-ABL binds to IRS-1 and IRS-1 phosphorylation is inhibited by imatinib in K562 cells. FEBS Letters, 2003, 535, 17-22.	2.8	27
59	Increased adhesive and inflammatory properties in blood outgrowth endothelial cells from sickle cell anemia patients. Microvascular Research, 2013, 90, 173-179.	2.5	27
60	Molecular Heterogeneity of G6PD Deficiency in an Amazonian Population and Description of Four New Variants. Blood Cells, Molecules, and Diseases, 2002, 28, 399-406.	1.4	26
61	Inhibition of caspaseâ€dependent spontaneous apoptosis via a cAMPâ€protein kinase A dependent pathway in neutrophils from sickle cell disease patients. British Journal of Haematology, 2007, 139, 148-158.	2.5	25
62	Reduced rate of sickleâ€related complications in Brazilian patients carrying HbFâ€promoting alleles at the BCL11A and HMIPâ€2 loci. British Journal of Haematology, 2016, 173, 456-460.	2.5	25
63	Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 450-461.	3.8	25
64	Increased adhesive properties of platelets in sickle cell disease: roles for Î±_{IIb}Î²₃â€mediated ligand binding, diminished cAMP signalling and increased phosphodiesterase 3A activity. British Journal of Haematology, 2010, 149, 280-288.	2.5	24
65	Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 168, 76-89.	4.3	24
66	IL10 inversely correlates with the percentage of CD8+ cells in MDS patients. Leukemia Research, 2013, 37, 541-546.	0.8	23
67	Characterization of a novel decellularized bone marrow scaffold as an inductive environment for hematopoietic stem cells. Biomaterials Science, 2019, 7, 1516-1528.	5.4	23
68	LEF1â€AS1, long nonâ€coding RNA, inhibits proliferation in myeloid malignancy. Journal of Cellular and Molecular Medicine, 2019, 23, 3021-3025.	3.6	23
69	3D Scaffolds to Model the Hematopoietic Stem Cell Niche: Applications and Perspectives. Materials, 2021, 14, 569.	2.9	23
70	Mutations in the p53 Gene in Acute Myeloid Leukemia Patients Correlate with Poor Prognosis. Hematology, 2002, 7, 13-19.	1.5	22
71	Regulation of Chondrogenesis by Transforming Growth Factor-ÃŸ3 and Insulin-like Growth Factor-1 from Human Mesenchymal Umbilical Cord Blood Cells. Journal of Rheumatology, 2010, 37, 1519-1526.	2.0	22
72	Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 1404-1411.	4.1	22

#	Article	IF	Citations
73	Immunophenotyping in Myelodysplastic Syndromes Can Add Prognostic Information to Well-Established and New Clinical Scores. PLoS ONE, 2013, 8, e81048.	2.5	22
74	(â€“)-Epigallocatechin-3-gallate induces apoptosis and differentiation in leukaemia by targeting reactive oxygen species and PIN1. Scientific Reports, 2021, 11, 9103.	3.3	22
75	Molecular matching for Rh and K reduces red blood cell alloimmunisation in patients with myelodysplastic syndrome. Blood Transfusion, 2015, 13, 53-8.	0.4	22
76	Increased adhesive properties of eosinophils in sickle cell disease. Experimental Hematology, 2004, 32, 728-734.	0.4	21
77	Identification of novel candidate genes for globin regulation in erythroid cells containing large deletions of the human Î²-globin gene cluster. Blood Cells, Molecules, and Diseases, 2006, 37, 82-90.	1.4	21
78	Haematopoietic response and bclâ€2 expression in patients with acute myeloid leukaemia. European Journal of Haematology, 1999, 62, 38-42.	2.2	21
79	InÂvitro microfluidic model for the study of vaso-occlusive processes. Experimental Hematology, 2015, 43, 223-228.	0.4	21
80	Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia. European Journal of Cancer, 2015, 51, 2076-2085.	2.8	21
81	Liver transplantation in a patient with S??O-thalassemia.. Transplantation, 2002, 74, 896-898.	1.0	20
82	ARHGAP21 associates with FAK and PKCÎ¶ and is redistributed after cardiac pressure overload. Biochemical and Biophysical Research Communications, 2008, 374, 641-646.	2.1	20
83	CXCR7 participates in CXCL12-mediated migration and homing of leukemic and normal hematopoietic cells. Stem Cell Research and Therapy, 2018, 9, 34.	5.5	20
84	Exosomes in the serum of Acute Myeloid Leukemia patients induce dendritic cell tolerance: Implications for immunotherapy. Vaccine, 2019, 37, 1377-1383.	3.8	20
85	CATS (FAM64A) abnormal expression reduces clonogenicity of hematopoietic cells. Oncotarget, 2016, 7, 68385-68396.	1.8	20
86	IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. Oncotarget, 2016, 7, 6948-6959.	1.8	20
87	Apoptosis-Regulating Proteins and Prognosis in Diffuse Large B Cell Non-Hodgkinâ€™s Lymphomas. Acta Haematologica, 2002, 107, 29-34.	1.4	19
88	51Cr-EDTA measurements of the glomerular filtration rate in patients with sickle cell anaemia and minor renal damage. Nuclear Medicine Communications, 2006, 27, 959-962.	1.1	19
89	Inhibition of phosphodiesterase 9A reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anemia individuals. Inflammation Research, 2011, 60, 633-642.	4.0	19
90	Altered red cell and platelet adhesion in hemolytic diseases: Hereditary spherocytosis, paroxysmal nocturnal hemoglobinuria and sickle cell disease. Clinical Biochemistry, 2013, 46, 1798-1803.	1.9	19

#	Article	IF	Citations
91	Reactive oxygen species production triggers green tea-induced anti-leukaemic effects on acute promyelocytic leukaemia model. Cancer Letters, 2018, 414, 116-126.	7.2	19
92	Association of glucose-6-phosphate dehydrogenase deficiency and X-linked chronic granulomatous disease in a child with anemia and recurrent infections. American Journal of Hematology, 2004, 75, 151-156.	4.1	18
93	Distinct expression profiles of MSI2 and NUMB genes in myelodysplastic syndromes and acute myeloid leukemia patients. Leukemia Research, 2012, 36, 1300-1303.	0.8	18
94	Tenâ€Elevenâ€Translocation 2 (<scp>TET</scp>2) is downregulated in myelodysplastic syndromes. European Journal of Haematology, 2015, 94, 413-418.	2.2	18
95	The effects of exchange transfusion for prevention of complications during pregnancy of sickle hemoglobin C disease patients. Transfusion, 2016, 56, 119-124.	1.6	18
96	Hematopoietic defects in response to reduced Arhgap21. Stem Cell Research, 2018, 26, 17-27.	0.7	18
97	The Gly972Arg Polymorphism in Insulin Receptor Substrate-1 Is Associated With Decreased Birth Weight in a Population-Based Sample of Brazilian Newborns. Diabetes Care, 2002, 25, 550-553.	8.6	16
98	Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms. Diagnostic Pathology, 2016, 11, 28.	2.0	16
99	Small Particles, Big Effects: The Interplay Between Exosomes and Dendritic Cells in Antitumor Immunity and Immunotherapy. Cells, 2019, 8, 1648.	4.1	16
100	A recurrent frameshift mutation of the ankyrin gene associated with severe hereditary spherocytosis. British Journal of Haematology, 2000, 111, 1190-1193.	2.5	16
101	Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells. Oncotarget, 2015, 6, 29573-29584.	1.8	16
102	Risk factors for conjunctival and retinal vessel alterations in sickle cell disease. Acta Ophthalmologica, 2006, 84, 234-241.	0.3	15
103	BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine. Haematologica, 2016, 101, e445-e448.	3.5	15
104	Natural Type II Collagen Hydrogel, Fibrin Sealant, and Adipose-Derived Stem Cells as a Promising Combination for Articular Cartilage Repair. Cartilage, 2017, 8, 439-443.	2.7	15
105	Rabbit antithymocyte globulin dose does not affect response or survival as first-line therapy for acquired aplastic anemia: a multicenter retrospective study. Annals of Hematology, 2018, 97, 2039-2046.	1.8	15
106	Reduction of AHSP synthesis in hemin-induced K562 cells and EPO-induced CD34+ cells leads to Î±-globin precipitation, impairment of normal hemoglobin production, and increased cell death. Experimental Hematology, 2008, 36, 265-272.	0.4	14
107	Identification of protein-coding and non-coding RNA expression profiles in CD34+and in stromal cells in refractory anemia with ringed sideroblasts. BMC Medical Genomics, 2010, 3, 30.	1.5	14
108	Imatinib restores VASP activity and its interaction with Zyxin in BCRâ€“ABL leukemic cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 388-395.	4.1	14

#	Article	IF	Citations
109	Cytokine polymorphisms in sickle cell disease and the relationship withÂcytokine expression. Experimental Hematology, 2016, 44, 583-589.	0.4	14
110	Fatty acid is a potential agent for bone tissue induction: InÂvitro and inÂvivo approach. Experimental Biology and Medicine, 2017, 242, 1765-1771.	2.4	14
111	Differences in heme and hemopexin content in lipoproteins from patients with sickle cell disease. Journal of Clinical Lipidology, 2018, 12, 1532-1538.	1.5	14
112	Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Hematology, Transfusion and Cell Therapy, 2021, 43, 341-348.	0.2	14
113	Association of the G-463A myeloperoxidase polymorphism with infection in sickle cell anemia. Haematologica, 2005, 90, 977-9.	3.5	14
114	Upâ€regulation of NADPH oxidase components and increased production of interferonâ€gamma by leukocytes from sickle cell disease patients. American Journal of Hematology, 2008, 83, 41-45.	4.1	13
115	Mesenchymal stromal cells from adipose tissue attached to suture material enhance the closure of enterocutaneous fistulas in a rat model. Cytotherapy, 2014, 16, 1709-1719.	0.7	13
116	The Cratylia mollis Seed Lectin Induces Membrane Permeability Transition in Isolated Rat Liver Mitochondria and a Cyclosporine Aâ€insensitive Permeability Transition in Trypanosoma cruzi Mitochondria. Journal of Eukaryotic Microbiology, 2014, 61, 381-388.	1.7	13
117	Upâ€regulation of <scp>SPINT</scp>2/<scp>HAI</scp>â€2 by Azacytidine in bone marrow mesenchymal stromal cells affects leukemic stem cell survival and adhesion. Journal of Cellular and Molecular Medicine, 2019, 23, 1562-1571.	3.6	13
118	Expressions of KLF1, FOXO3a, HOOK3 and MIER1 genes Are Associated with Fetal Hemoglobin Levels in Hereditary Persistence of Fetal Hemoglobin,. Blood, 2011, 118, 3195-3195.	1.4	13
119	Protective effect of green tea and epigallocatechin-3-gallate in a LPS-induced systemic inflammation model. Journal of Nutritional Biochemistry, 2022, 101, 108920.	4.2	13
120	Obesity and inflammation and the effect on the hematopoietic system. Revista Brasileira De Hematologia E Hemoterapia, 2014, 36, 147-151.	0.7	12
121	Pilot randomized controlled trial to evaluate the effect of aquatic and land physical therapy on musculoskeletal dysfunction of sickle cell disease patients. Revista Brasileira De Hematologia E Hemoterapia, 2015, 37, 82-89.	0.7	12
122	Sickle cell/Î²-thalassemia: Comparison of SÎ²⁰ and SÎ²⁺ Brazilian patients followed at a single institution. Hematology, 2016, 21, 623-629.	1.5	12
123	Progesterone Upregulates GATA-1 on Erythroid Progenitors Cells in Liquid Culture. Blood Cells, Molecules, and Diseases, 2002, 29, 213-224.	1.4	11
124	Platelet associated IgG may be related with thrombocytopenia in patients with myelodysplastic syndromes. Leukemia Research, 2012, 36, 554-559.	0.8	11
125	YAP1expression in myelodysplastic syndromes and acute leukemias. Leukemia and Lymphoma, 2014, 55, 2413-2415.	1.3	11
126	Abnormal Hedgehog pathway in myelodysplastic syndrome and its impact on patients' outcome. Haematologica, 2015, 100, e491-e493.	3.5	11

#	Article	IF	Citations
127	Telomere length correlates with disease severity and inflammation in sickle cell disease. Revista Brasileira De Hematologia E Hemoterapia, 2017, 39, 140-145.	0.7	11
128	Novel mutations associated with pyruvate kinase deficiency in Brazil. Hematology, Transfusion and Cell Therapy, 2018, 40, 5-11.	0.2	11
129	Obesity as a Possible Risk Factor for Progression from Monoclonal Gammopathy of Undetermined Significance Progression into Multiple Myeloma: Could Myeloma Be Prevented with Metformin Treatment?. Advances in Hematology, 2021, 2021, 1-7.	1.0	11
130	G6PD SumarÃ©: A novel mutation in the G6PD gene (1292 Tâ†'G) associated with chronic nonspherocytic anemia. , 1997, 10, 245-247.		10
131	Polymorphisms of interleukin-1 gene complex, IL6 and tumour necrosis factor genes in chronic idiopathic neutropenia of adults. Annals of Hematology, 2005, 84, 709-714.	1.8	10
132	Postâ€translational modification of the RhoGTPase activating protein 21, ARHGAP21, by SUMO2/3. FEBS Letters, 2012, 586, 3522-3528.	2.8	10
133	Autologous Platelet Gel. International Journal of Lower Extremity Wounds, 2014, 13, 120-126.	1.1	10
134	Deferasirox associated with liver failure and death in a sickle cell anemia patient homozygous for the â^'1774delG polymorphism in the Abcc2 gene. Clinical Case Reports (discontinued), 2017, 5, 1218-1221.	0.5	10
135	S100A8 acts as an autocrine priming signal for heme-induced human MÏ• pro-inflammatory responses in hemolytic inflammation. Journal of Leukocyte Biology, 2019, 106, 35-43.	3.3	10
136	An update on arginine in sickle cell disease. Expert Review of Hematology, 2019, 12, 235-244.	2.2	10
137	Artesunate Switches Monocytes to an Inflammatory Phenotype with the Ability to Kill Leukemic Cells. International Journal of Molecular Sciences, 2021, 22, 608.	4.1	10
138	Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDS. Blood, 2011, 118, 461-461.	1.4	10
139	Enalapril therapy and cardiac remodelling in sickle cell disease patients. Acta Cardiologica, 2008, 63, 599-602.	0.9	10
140	Altered Functional Properties of Eosinophils In Sickle Cell Anemia and Effects of Hydroxyurea Therapy. Blood, 2010, 116, 2656-2656.	1.4	10
141	Ndfip Is a Novel Autophagy Regulator and It Is Deregulated In Acute Myeloid Leukemia. Blood, 2013, 122, 1419-1419.	1.4	10
142	?-cardiac actin (ACTC) binds to the band 3 (AE1) cardiac isoform. Journal of Cellular Biochemistry, 2003, 89, 1215-1221.	2.6	9
143	Band 3Tambau: a de novo mutation in the AE1 gene associated with hereditary spherocytosis. Implications for anion exchange and insertion into the red blood cell membrane. European Journal of Haematology, 2005, 74, 396-401.	2.2	9
144	PIP4KIIA and Î²â€globin: transcripts differentially expressed in reticulocytes and associated with high levels of Hb H in two siblings with Hb H disease. European Journal of Haematology, 2009, 83, 490-493.	2.2	9

#	Article	IF	Citations
145	Effects of thalidomide on long-term bone marrow cultures from patients with myelodysplastic syndromes: Induction of IL-10 expression in the stromal layers. Leukemia Research, 2011, 35, 1102-1107.	0.8	9
146	Î²â€Spectrin Campinas: a novel shortened Î²â€chain variant associated with skipping of exon 30 and hereditary elliptocytosis. British Journal of Haematology, 1997, 97, 579-585.	2.5	8
147	Simple fluorescent PCR method for detection of large deletions in the ?-globin gene cluster. American Journal of Hematology, 2003, 72, 225-227.	4.1	8
148	Phylogenetic Analysis of RhoGAP Domain-Containing Proteins. Genomics, Proteomics and Bioinformatics, 2006, 4, 182-188.	6.9	8
149	Alterations in cell maturity and serum survival factors may modulate neutrophil numbers in sickle cell disease. Experimental Biology and Medicine, 2011, 236, 1239-1246.	2.4	8
150	MDR-1 and GST polymorphisms are involved in myelodysplasia progression. Leukemia Research, 2013, 37, 970-973.	0.8	8
151	Serine Protease Inhibitor Kunitz-Type 2 Is Downregulated in Myelodysplastic Syndromes and Modulates Cellâ€“Cell Adhesion. Stem Cells and Development, 2014, 23, 1109-1120.	2.1	8
152	Umbilical cord blood <scp>CD</scp>34⁺ stem cells and other mononuclear cell subtypes processed up to 96Âh from collection and stored at room temperature maintain a satisfactory functionality for cell therapy. Vox Sanguinis, 2015, 108, 72-81.	1.5	8
153	The U2AF homology motif kinase 1 (UHMK1) is upregulated upon hematopoietic cell differentiation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 959-966.	3.8	8
154	Reduced expression of NR4A1 activates glycolytic pathway in acute promyelocytic leukemia cells. Leukemia and Lymphoma, 2018, 59, 1501-1504.	1.3	8
155	The challenges of handling deferasirox in sickle cell disease patients older than 40 years. Hematology, 2019, 24, 596-600.	1.5	8
156	Immunomodulatory Effect of Green Tea Treatment in Combination with Low-dose Chemotherapy in Elderly Acute Myeloid Leukemia Patients with Myelodysplasia-related Changes. Integrative Cancer Therapies, 2021, 20, 153473542110026.	2.0	8
157	Polyphenolic Flavonoid Compound Quercetin Effects in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Molecules, 2021, 26, 5781.	3.8	8
158	Rac GTPases in acute myeloid leukemia cells: Expression profile and biological effects of pharmacological inhibition. Toxicology and Applied Pharmacology, 2022, 442, 115990.	2.8	8
159	Î²-Spectrin StaBÃ¡rbara: a novel frameshift mutation in hereditary spherocytosis associated with detectable levels of mRNA and a germ cell line mosaicism. British Journal of Haematology, 2001, 115, 347-353.	2.5	7
160	Arginine 490 is a hot spot for mutation in the band 3 gene in hereditary spherocytosis. European Journal of Haematology, 1999, 63, 360-361.	2.2	7
161	ARHGAP21 deficiency impairs hepatic lipid metabolism and improves insulin signaling in lean and obese mice. Canadian Journal of Physiology and Pharmacology, 2019, 97, 1018-1027.	1.4	7
162	Whole-exome sequencing indicates FLG2 variant associated with leg ulcers in Brazilian sickle cell anemia patients. Experimental Biology and Medicine, 2019, 244, 932-939.	2.4	7

#	Article	IF	Citations
163	NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, 2021, 39, 736-746.	2.6	7
164	Hematopoietic Cell Kinase (HCK) Is a Player of the Crosstalk Between Hematopoietic Cells and Bone Marrow Niche Through CXCL12/CXCR4 Axis. Frontiers in Cell and Developmental Biology, 2021, 9, 634044.	3.7	7
165	SDF-1 Signaling in Myeloid Malignancies,. Blood, 2011, 118, 3824-3824.	1.4	7
166	ANKHD1 Is Essential for Repair of DNA Double-Strand Breaks in Multiple Myeloma. Blood, 2015, 126, 1762-1762.	1.4	7
167	Differential profile of PIP4K2A expression in hematological malignancies. Blood Cells, Molecules, and Diseases, 2015, 55, 228-235.	1.4	6
168	Transfusion service management of sickleâ€cell disease patients. Vox Sanguinis, 2016, 110, 288-294.	1.5	6
169	Coinheritance of Hb Bristol-Alesha [Î²67(E11)Valâ†'Met;HBB: c.202G>A] and the Î±212 Patchwork Allele in a Brazilian Child with Severe Congenital Hemolytic Anemia. Hemoglobin, 2017, 41, 203-208.	0.8	6
170	Recombinant erythropoietin as alternative to red cell transfusion in sickle cell disease. Vox Sanguinis, 2019, 114, 178-181.	1.5	6
171	Mild hemolysis in a girl with G6PD SumarÃ© (class I variant) associated with G6PD Aâ^'. Blood Cells, Molecules, and Diseases, 2003, 30, 238-240.	1.4	5
172	Regulation of the GATA3 promoter by human T-cell lymphotropic virus type I Tax protein. Journal of Cellular Biochemistry, 2004, 93, 1178-1187.	2.6	5
173	Artesunate strongly modulates myeloid and regulatory T cells to prevent LPS-induced systemic inflammation. Biomedicine and Pharmacotherapy, 2021, 143, 112211.	5.6	5
174	Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia. Cancer Immunology, Immunotherapy, 2022, 71, 1909-1921.	4.2	5
175	TGF-Î²1 Reduces Neutrophil Adhesion and Prevents Acute Vaso-Occlusive Processes in Sickle Cell Disease Mice. Cells, 2022, 11, 1200.	4.1	5
176	Accelerated lowâ€density neutrophil transition in sickle cell anaemia may contribute to disease pathophysiology. British Journal of Haematology, 2022, 197, 232-235.	2.5	5
177	Reduced expression of FLIPSHORT in bone marrow of low risk myelodysplastic syndrome. Leukemia Research, 2007, 31, 853-857.	0.8	4
178	Lack of association between MDM2 SNP309 and TP53 Arg72Pro polymorphisms with clinical outcomes in myelodysplastic syndrome. Neoplasma, 2012, 59, 530-535.	1.6	4
179	Gene Expression Analysis of the Brazilian Type of Hereditary Persistence of Fetal Hemoglobin: Identification of Genes that Could be Related to Î³-Globin Activation. Hemoglobin, 2013, 37, 516-535.	0.8	4
180	Amputations in Sickle Cell Disease: Case Series and Literature Review. Hemoglobin, 2016, 40, 150-155.	0.8	4

#	Article	IF	Citations
181	Hypocholesterolemia and dysregulated production of angiopoietin-like proteins in sickle cell anemia patients. Cytokine, 2019, 120, 88-91.	3.2	4
182	ANKHD1 is an S phase protein required for histone synthesis and DNA repair in multiple myeloma cells. Blood Cells, Molecules, and Diseases, 2020, 84, 102460.	1.4	4
183	Effects of RhoA and RhoC upon the sensitivity of prostate cancer cells to glutamine deprivation. Small GTPases, 2021, 12, 20-26.	1.6	4
184	Deficiency of ARHGAP21 alters megakaryocytic cell lineage responses and enhances platelet hemostatic function. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 119012.	4.1	4
185	NRF2 Is Targeted By the Polyphenol Quercetin and Induces Apoptosis, in Part, through up Regulation of Pro Apoptotic Mirs. Blood, 2019, 134, 2529-2529.	1.4	4
186	Hedgehog Pathway Is Deregulated In Myelodysplastic Syndrome Progenitor Bone Marrow Cells. Blood, 2013, 122, 1533-1533.	1.4	4
187	HPFH and Delta-Beta Thalassemia Have Different Profiles Of Micrornas and Transcription Factors. Blood, 2013, 122, 186-186.	1.4	4
188	Haplotype analysis andAÎ³ gene polymorphism associated with the Brazilian type of hereditary persistence of fetal hemoglobin. , 1998, 58, 49-54.		3
189	Characterisation of a new splice variant of MASK-BP3ARF and MASK human genes, and their expression patterns during haematopoietic cell differentiation. Gene, 2005, 363, 113-122.	2.2	3
190	High Levels of Human Î³-Globin are Expressed in Adult Mice Carrying a Transgene of the Brazilian Type of Hereditary Persistence of Fetal Hemoglobin (^AÎ³ â^'195). Hemoglobin, 2009, 33, 439-447.	0.8	3
191	Pyrimidine-5â€²-nucleotidase Campinas, a new mutation (p.R56G) in the NT5C3 gene associated with pyrimidine-5â€²-nucleotidase type I deficiency and influence of Gilbert's Syndrome on clinical expression. Blood Cells, Molecules, and Diseases, 2014, 53, 246-252.	1.4	3
192	PIPKIIÎ± is widely expressed in hematopoietic-derived cells and may play a role in the expression of alpha- and gamma-globins in K562 cells. Molecular and Cellular Biochemistry, 2014, 393, 145-153.	3.1	3
193	Overexpression and Characterization of the C-Terminal Domain of Human SIVA1: A Proapoptotic Factor and Cytoskeleton Binding Protein. Protein and Peptide Letters, 2015, 23, 43-50.	0.9	3
194	Guidelines on neonatal screening and painful vaso-occlusive crisis in sickle cell disease: AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Revista Brasileira De Hematologia E Hemoterapia, 2016, 38, 147-157.	0.7	3
195	CXCR4hi effector neutrophils in sickle cell anemia: potential role for elevated circulating serotonin (5-HT) in CXCR4hi neutrophil polarization. Scientific Reports, 2020, 10, 14262.	3.3	3
196	Prevalence of Bartonella spp. Infection in Patients with Sickle Cell Disease. Vector-Borne and Zoonotic Diseases, 2020, 20, 509-512.	1.5	3
197	New germline GATA1 variant in females with anemia and thrombocytopenia. Blood Cells, Molecules, and Diseases, 2021, 88, 102545.	1.4	3
198	Analysis of Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients: Preliminary Results of an Open Label Phase II Trial (FIBROMET). Blood, 2019, 134, 554-554.	1.4	3

#	Article	IF	Citations
199	Inflammasome-Dependent IL-1Î² Release from Neutrophils in Human Sickle Cell Anemia. Blood, 2016, 128, 854-854.	1.4	3
200	Increased Angiogenic Activity of Plasma From Sickle Cell Disease Patients and Anti-Angiogenic Effects of Hydroxyurea: Evaluation of Capillary-Like Structure Formation of Human Umbilical Vein Endothelial Cells on Matrigel. Blood, 2011, 118, 899-899.	1.4	3
201	Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes. Clinics, 2011, 66, 793-9.	1.5	3
202	Reduced blood pressure in sickle cell disease is associated with decreased angiotensin converting enzyme (ACE) activity and is not modulated by ACE inhibition. PLoS ONE, 2022, 17, e0263424.	2.5	3
203	Association of the Î±-spectrin R28H mutation with allele Î±LELY and with Î±I/Î±II domain haplotypes in three Brazilian families. European Journal of Haematology, 2000, 64, 53-58.	2.2	2
204	Lack of Arg972 Polymorphism in the IRS1 Gene in Parakana Brazilian Indians. Human Biology, 2004, 76, 147-151.	0.2	2
205	Motivating medical students to learn basic science concepts using chronic myeloid leukemia as an integration theme. Revista Brasileira De Hematologia E Hemoterapia, 2015, 37, 63-66.	0.7	2
206	Differential profile of CDKN1A and TP53 expressions in bone marrow mesenchymal stromal cells from myeloid neoplasms. Revista Brasileira De Hematologia E Hemoterapia, 2016, 38, 368-370.	0.7	2
207	Interactions of sickle red blood cells with neutrophils are stabilized on endothelial cell layers. Blood Cells, Molecules, and Diseases, 2016, 56, 38-40.	1.4	2
208	Lithium, a classic drug in psychiatry, improves nilotinib-mediated antileukemic effects. Biomedicine and Pharmacotherapy, 2018, 99, 237-244.	5.6	2
209	Echocardiografic abnormalities in patients with sickle cell/Î²-thalassemia do not depend on the Î²-thalassemia phenotype. Hematology, Transfusion and Cell Therapy, 2019, 41, 158-163.	0.2	2
210	Technetium-99m-dimercaptosuccinic acid renal scintigraphy and single photon emission computed tomography/computed tomography in patients with sickle cell disease. Nuclear Medicine Communications, 2019, 40, 1158-1165.	1.1	2
211	Familial Mastocytosis: Identification Of KIT K509I Mutation and Its In Vitro Sensitivity To Imatinib, Dasatinib and PKC412. Blood, 2013, 122, 5267-5267.	1.4	2
212	Coagulation Activation By Heme: Evidence from Global Hemostasis Assays. Blood, 2014, 124, 455-455.	1.4	2
213	Leukocyte Telomere Length Correlates with Disease Severity and Inflammation in Sickle Cell Disease. Blood, 2015, 126, 2173-2173.	1.4	2
214	Mutations in Triple-Negative Patients with Myeloproliferative Neoplasms. Blood, 2019, 134, 5395-5395.	1.4	2
215	Arhgap21 Deficiency Results in Increase of Osteoblastic Lineage Cells in the Murine Bone Marrow Microenvironment. Frontiers in Cell and Developmental Biology, 2021, 9, 718560.	3.7	2
216	DNAase I hypersensitive site 3' to the beta-globin gene cluster contains a TAA insertion specific for beta(S)-Benin haplotype. Haematologica, 2002, 87, 246-9.	3.5	2

#	Article	IF	Citations
217	A NOVELÎ²-GLOBIN VARIANT: Hb POÃ‡OS DE CALDAS [Î²61(E5)Lysâ†'Gln]. Hemoglobin, 2002, 26, 385-388.	0.8	1
218	Unsuccessful treatment of sideroblastic anaemia with chloroquine. Revista Brasileira De Hematologia E Hemoterapia, 2003, 25, 67.	0.7	1
219	Low expression of tissue inhibitor of metalloproteinase-2 may be associated with high-risk myelodysplastic syndrome. Leukemia and Lymphoma, 2013, 54, 1091-1093.	1.3	1
220	Myelodysplastic syndrome with synchronous gastric cancer: when the symptoms suggest something else. Revista Brasileira De Hematologia E Hemoterapia, 2014, 36, 442-444.	0.7	1
221	Stathmin 1 expression in plasma cell neoplasms. Revista Brasileira De Hematologia E Hemoterapia, 2017, 39, 183-185.	0.7	1
222	Effectiveness of a home-based therapeutic exercise program on lower back pain and functionality in Sickle Cell Disease (SCD) patients. Hematology, Transfusion and Cell Therapy, 2021, 43, 268-279.	0.2	1
223	Novel Non-Coding Transcript in NR4A3 Locus, LncNR4A3, Regulates RNA Processing Machinery Proteins and NR4A3 Expression. Frontiers in Oncology, 2020, 10, 569668.	2.8	1
224	Effects of home-based inspiratory muscle training on sickle cell disease (SCD) patients. Hematology, Transfusion and Cell Therapy, 2021, 43, 443-452.	0.2	1
225	Evaluation of different protocols for culturing mesenchymal stem cells derived from murine bone marrow. Hematology, Transfusion and Cell Therapy, 2021, , .	0.2	1
226	Hydroxyurea Reduces the Hypercoagulable State In Sickle Cell Anemia. Blood, 2011, 118, 1068-1068.	1.4	1
227	Proangiogenic Effects of Plasma From Sickle Cell Disease Patients and Antiangiogenic Effects of Hydroxyurea: Evaluation of Invasion and Proliferation of Human Endothelial Cells and Effects of Hydroxyurea in a Mouse Matrigel Plug Neovascularization Assay. Blood, 2012, 120, 377-377.	1.4	1
228	Monocyte Shift to a Non-Classical CD14dim/CD16+ Phenotype Correlates with Fetal Hemoglobin Levels in Sickle Cell Anemia Patients Treated with Hydroxyurea. Blood, 2012, 120, 817-817.	1.4	1
229	Cytokines Polymorphisms and Relationship with Cytokine Expression in Sickle Cell Disease. Blood, 2014, 124, 4910-4910.	1.4	1
230	Natural Scaffold, from Bovine Bone Marrow, Reproduces Native Microenvironment and Supports CD34+ and Stromal Cells. Blood, 2015, 126, 2400-2400.	1.4	1
231	A Novel Antisense Long Noncoding RNA Modulates NR4A1 Protein Level in Myeloid Malignancies. Blood, 2015, 126, 2442-2442.	1.4	1
232	Elevated Plasma Levels and Platelet-Associated Expression of the Pro-Thrombotic and Pro-Inflammatory Protein, LIGHT (TNFSF14), In Sickle Cell Anemia (SCA). Blood, 2010, 116, 2651-2651.	1.4	1
233	In Vitro and In Vivo downregulation of Leukemogenesis by FMNL1 Inhibition In Namalwa Cell Line. Blood, 2011, 118, 1485-1485.	1.4	1
234	Hepcidin Production in Ineffective Erythropoiesis and Chronic Hemolysis: Insights on the Crosstalk Between Erythropoiesis and Iron Metabolism. Blood, 2011, 118, 346-346.	1.4	1

#	Article	IF	Citations
235	Abnormal Expression of Ndfip2 and Cbl in Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: Role of Ubiquitin Proteasome System in Myeloid Neoplasms and Normal Hematopoiesis. Blood, 2011, 118, 2567-2567.	1.4	1
236	Imaging Flow Cytometry and Microfluidic Flow Assays Demonstrate Heterocellular Aggregation Of Immature Sickle Erythrocytes To Neutrophils Via Mac-1/VLA-4 Interactions. Blood, 2013, 122, 318-318.	1.4	1
237	Inhibition Of the Rho/Rho-Kinase Pathway Reduces In Vitro Adhesion Of Sickle Cell Anemia Eosinophils To Human Endothelial Cells. Blood, 2013, 122, 2219-2219.	1.4	1
238	Hematopoietic Cell Kinase (HCK) Is Involved in Myelodysplastic Syndromes and Acute Leukemia Pathophysiology By Modulating PI3K Pathway and Enhancing Erythroid Differentiation. Blood, 2014, 124, 1891-1891.	1.4	1
239	Repeat Course of Rabbit Antithymocyte Globulin As Salvage Following Initial Therapy with Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia. Blood, 2014, 124, 2944-2944.	1.4	1
240	Analysis of the Eligibility of Patients with Sickle Cell Disease for Palliative Care. Blood, 2019, 134, 4681-4681.	1.4	1
241	Final Results of the Fibromet Trial: An Open Label Phase II Study to Evaluate Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients. Blood, 2021, 138, 2584-2584.	1.4	1
242	DNAase I hypersensitive site 3' to the beta-globin gene cluster containing two TAA insertions and a G-->A polymorphism is predominantly associated with the beta+-thalassemia IVS-I-6 (T-->C) mutation. Hemoglobin, 2005, 29, 85-9.	0.8	1
243	Relationship Between the Type of BCR-ABL Rearrangement and Bone Marrow Histopathological Features in Chronic Myeloid Leukemia. Acta OncolÃ³gica, 1997, 36, 313-315.	1.8	0
244	DNAase I Hypersensitive Site 3â€² to the Î²-Globin Gene Cluster Containing Two TAA Insertions and a Gâ†'A Polymorphism is Predominantly Associated with the Î²+-Thalassemia IVS-I-6 (Tâ†'C) Mutation. Hemoglobin, 2005, 29, 85-89.	0.8	0
245	Fermented papaya preparation for Î²-thalassemia?. Expert Review of Hematology, 2010, 3, 265-268.	2.2	0
246	Guidelines on the treatment of anemia of chronic renal failure using recombinant human erythropoietin: AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: AssociaÃ§Ã£o MÃ©dica Brasileira â€“ 2014. Revista Brasileira De Hematologia E Hemoterapia, 2014, 36, 450-453.	0.7	0
247	LDH and age are associated with hemolysis-endothelial dysfunction in HbSC patients. Blood Cells, Molecules, and Diseases, 2016, 59, 119-123.	1.4	0
248	IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes. Hematology, Transfusion and Cell Therapy, 2018, 40, 92-95.	0.2	0
249	Ex Vivo Manufacture of Megakaryocytes and Platelets from Stem Cells: Recent Advances Toward Transfusion in Humans. Stem Cells and Development, 2021, 30, 351-362.	2.1	0
250	Platelet counts on peripheral blood and Mean Platelet Volume as markers of clinical severity in Sickle Cell Disease. Blood Cells, Molecules, and Diseases, 2021, 91, 102592.	1.4	0
251	Artemisinins induce endoplasmic reticulum stress in acute leukaemia cells in vitro and in vivo. EJHaem, 2021, 2, 818.	1.0	0
252	Platelet-Associated IgG May Be Associated with Thrombocytopenia In Patients with Myelodysplastic Syndromes. Blood, 2010, 116, 2943-2943.	1.4	0

#	Article	IF	Citations
253	Formin-Like 1 (FMNL1) Associates with Rac1 and Negatively Regulates Neoplastic Growth and Migration in Leukemia Cell Lines.. Blood, 2010, 116, 1030-1030.	1.4	0
254	IRS2 Is Dowregulated In Primary MDS Cells and During MDS Erythroid Differentiation. Blood, 2010, 116, 1886-1886.	1.4	0
255	Knockdown of Insulin Receptor Substrate 1 (IRS1); a Partner of BCR-ABL, Results In Decrease In Proliferation and Downregulation of AKT/mTOR and MAPK Pathways In K562 Cells. Blood, 2010, 116, 4459-4459.	1.4	0
256	Hydroxyurea Induces Hepcidin Expression In Monocytes In Sickle Cell Anemia Patients. Blood, 2010, 116, 2653-2653.	1.4	0
257	ANKHD1 Silencing Induces S-Phase Arrest and Modulates Cell Cycle Gene Expression in Human Myeloma Cells. Blood, 2011, 118, 1828-1828.	1.4	0
258	Th17/Treg Imbalance in Sickle Cell Disease and Hydroxyurea Therapy. Blood, 2011, 118, 1050-1050.	1.4	0
259	Adhesive and Inflammatory Properties Are Increased in Blood Outgrowth Endothelial Cells From Patients with Sickle Cell Anemia. Blood, 2011, 118, 2133-2133.	1.4	0
260	The CALM/AF10 Interactor CATS Is a Substrate of KIS, a Positive Regulator of Cell Cycle Progression in Leukemia Cells. Blood, 2011, 118, 2549-2549.	1.4	0
261	Downregulation of IRS2 in Myelodysplastic Syndrome (MDS) May Be Related to Impaired Cell Differentiation,. Blood, 2011, 118, 3814-3814.	1.4	0
262	MDR-1 and GST Polymorphisms Are Involved in Myelodysplasia Progression,. Blood, 2011, 118, 3507-3507.	1.4	0
263	FMNL1 Is Involved in Immune Response and Hematopoietic Differentiation in MDS. Blood, 2011, 118, 1735-1735.	1.4	0
264	CXCR7 Is Highly Expressed in Acute Lymphoblastic Leukemia and Potentiates the Chemotactic Response to SDF-1. Blood, 2011, 118, 1482-1482.	1.4	0
265	Autophagy Regulation and Dysfunction in Bone Marrow Malignancies. Blood, 2012, 120, 4623-4623.	1.4	0
266	Elevation of Hypercoagulability Markers in Hemoglobin SC Disease. Blood, 2012, 120, 3227-3227.	1.4	0
267	Hematopoietic Cell Kinase (HCK) Is Highly Expressed in Myelodysplastic Syndrome (MDS) and Regulates Proliferation, Cell Cycle Progression and Hematopoietic Differentiation. Blood, 2012, 120, 3813-3813.	1.4	0
268	Hedgehog Ligands and Receptors Are Deregulated in Myelodysplastic Syndromes. Blood, 2012, 120, 3817-3817.	1.4	0
269	BNIP3 Is Downregulated in Myelodysplastic Syndromes and Acute Myeloid Leukemia and Is a Potential Molecular Target for Decitabine. Blood, 2012, 120, 1708-1708.	1.4	0
270	Reduced TET2 expression in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia.. Blood, 2012, 120, 2822-2822.	1.4	0

#	Article	IF	Citations
271	The Cytoskeleton Proteins VASP and Zyxin Participate in Hematopoiesis and in the BCR-ABL Signaling Pathway.. Blood, 2012, 120, 2780-2780.	1.4	0
272	Platelets From Sickle Cell Disease Individuals Induce Endothelial Activation, Demonstrating ICAM-1 and E-Selectin Adhesion Molecule Expression, Inflammatory Cytokine Production and Activation of NFÎºB Transcription Factor Gene Expression.. Blood, 2012, 120, 2114-2114.	1.4	0
273	Correlation Between IL10 and CD8+ Cells in MDS Patients Adds New Insight Into the Role of the Immune System in This Disease. Blood, 2012, 120, 3836-3836.	1.4	0
274	ANKHD1 Interacts with the Proapoptotic Protein SIVA and Plays a Role in the Proliferation and Stathmin Activation of Acute Leukemia Cells.. Blood, 2012, 120, 2419-2419.	1.4	0
275	PTK2 and PTPN11 expression in myelodysplastic syndromes. Clinics, 2013, 68, 1371-1375.	1.5	0
276	Quercetin Induces Autophagy, Apoptosis and Cell Cycle Arrest In P39 Cells. Blood, 2013, 122, 5042-5042.	1.4	0
277	IRS2 Associates With JAK2 and May Be Involved In Cell Proliferation Pathways In Chronic Myeloproliferative Neoplasms. Blood, 2013, 122, 1598-1598.	1.4	0
278	Green Tea In Acute Myeloid Leukemia. Blood, 2013, 122, 5032-5032.	1.4	0
279	Inflammasome and Autophagy Activation In Symptomatic Multiple Myeloma Could Predict Response To Thalidomide-Based Chemotherapy. Blood, 2013, 122, 3131-3131.	1.4	0
280	Antimyeloma In Vitro Activity Of 15-Deoxy-D12,14-Prostaglandin J2 Is Associated With Endoplasmic Reticulum Stress In a Reactive Oxygen Species-Dependent Fashion. Blood, 2013, 122, 4913-4913.	1.4	0
281	VASP Protein, a Binding Partner Of BCR-ABL and FAK, May Be Implicated In The Chronic Myeloid Leukemia Phenotype. Blood, 2013, 122, 5162-5162.	1.4	0
282	Increased Platelet-Derived CD40L May Modulate Endothelial Cell ICAM-1 Expression and Interact With Leukocytes In Sickle Cell Anemia. Blood, 2013, 122, 974-974.	1.4	0
283	ANKHD1 Silencing Reduces In Vitro Clonogenicity and In Vivo Tumorogenicity Of Multiple Myeloma Cells. Blood, 2013, 122, 3168-3168.	1.4	0
284	Stathmin 1 Is Involved In The Highly Proliferative Phenotype Of High-Risk Myelodysplastic Syndromes and Acute Leukemia Cells. Blood, 2013, 122, 861-861.	1.4	0
285	FMNL1 Is Downregulated In Myelodysplastic Syndromes and Is Involved In Megakaryocytic Differentiation. Blood, 2013, 122, 1519-1519.	1.4	0
286	Arhgap21 Expression in Bone Marrow Niche Is Crucial for Hematopoietic Progenitor Homing and Short Term Reconstitution after Transplantation. Blood, 2014, 124, 1591-1591.	1.4	0
287	BRD4 Short Isoform Is a Myelodysplasia Prognostic Marker Involved in Inappropriate DNA Damage Response. Blood, 2014, 124, 3234-3234.	1.4	0
288	ANKHD1 Is Required for S Phase Progression and Histone Gene Transcription in Multiple Myeloma. Blood, 2014, 124, 2002-2002.	1.4	0

#	Article	IF	Citations
289	Cellular and Molecular Effects of NVP-BKM120 in Lymphoblastic Leukemia Cells. Blood, 2014, 124, 2241-2241.	1.4	0
290	IRS2 Inhibition Reduces Cell Proliferation and Has Cumulative Effects with Ruxolitinib in JAK2 V617F Cells. Blood, 2014, 124, 3219-3219.	1.4	0
291	Stathmin 1 Silencing Amplifies Ruxolitinib-Induced Apoptosis in JAK2V617F Cells. Blood, 2014, 124, 3229-3229.	1.4	0
292	Randomized Clinical Trial to Evaluate the Effect of Two Physical Therapy Programs in Musculoskeletal Dysfunction in Subjects with Sickle Cell Disease. Blood, 2014, 124, 5982-5982.	1.4	0
293	Differentially Expressed Genes and Pathways in Endothelial Cells Exposed to Hemin or Plasma from Patients with Sickle Cell Disease: A Meta-Analysis of Gene Expression Studies. Blood, 2014, 124, 4018-4018.	1.4	0
294	Antisense Long Non-Coding RNA in the LEF1 Locus Regulates Sense LEF1 Expression in Leukemic Cell Line KG1. Blood, 2015, 126, 3586-3586.	1.4	0
295	Knockdown of HCK Reduces Cell Death and Erythroid Differentiation in Human CD34+ Hematopoietic Progenitor Cells. Blood, 2015, 126, 2860-2860.	1.4	0
296	Pharmacological IRS1/2 Inhibition Reduces Cell Viability in BCR-ABL1 Positive Cells. Blood, 2015, 126, 2772-2772.	1.4	0
297	ARHGAP21 Is Upregulated and Triggers the Modulation of Rho Gtpase Signaling Pathways during Megakaryocytic Differentiation. Blood, 2015, 126, 4760-4760.	1.4	0
298	Methylation of HAI-2/SPINT2 in Bone Marrow Mesenchymal Stromal Cells of MDS and AML Patients Affects Hematopoietic Stem Cell Survival and Adhesion. Blood, 2015, 126, 2847-2847.	1.4	0
299	CXCR7 Participates in Chemotaxis and Homing Mediated By CXCL12. Blood, 2015, 126, 3601-3601.	1.4	0
300	Modulation of Hemolytic and Hemoglobin/Heme Scavenging Profiles in Sickle Cell Anemia, Hereditary Spherocytosis and Paroxysmal Nocturnal Hemoglobinuria. Blood, 2016, 128, 1257-1257.	1.4	0
301	Pharmacological IRS1/2 Inhibition Induces Apoptosis in BCR-ABL1T315I mutant Cells. Blood, 2016, 128, 1886-1886.	1.4	0
302	ROS Production Triggers Anti-Leukemic Effects of Green Tea. Blood, 2016, 128, 5219-5219.	1.4	0
303	ANKHD1 Silencing Delays S Phase Progression in Multiple Myeloma Cells Via Activation of ATM/ATR -CDC25a Pathway. Blood, 2016, 128, 5624-5624.	1.4	0
304	Echocardiografic Abnormalities in Patients with Sickle Cell/Î²-Thalassemia Do Not Depend on the Î²-Thalassemia Phenotype. Blood, 2017, 130, 987-987.	1.4	0
305	Combined Administration of Recombinant TGF-Î²1 and DMSO Decreases the in Vitro Inflammatory Properties of Neutrophils from Sickle Cell Anemia Individuals. Blood, 2018, 132, 2366-2366.	1.4	0
306	Elevated Levels of Hepatokine Angiopoietin-like 3 Correlate Paradoxically with Hypocholesterolemia and Hemolysis in Sickle Cell Anemia. Blood, 2018, 132, 1069-1069.	1.4	0

#	Article	IF	Citations
307	Polyphenols Modulate Quiescence/Mobilization of Hematopoietic Immature Cells through APC/EPCR/PAR-1 Axis. Blood, 2018, 132, 3830-3830.	1.4	0
308	Epigallocatechin-3-Gallate Induces Cellular Differentiation and Reduces Leukemia Burden in PML/RarÎ± Mice By Increasing Reactive Oxygen Species and Reducing PIN1 Expression. Blood, 2019, 134, 5765-5765.	1.4	0
309	Expression of Notch Pathway Components in Primary Samples of Allogeneic Hematopoietic Cell Transplant Patients with Chronic Graft Versus Host Disease. Blood, 2019, 134, 5600-5600.	1.4	0
310	Quiescence/Mobilization of Hematopoietic Immature Cells Induced By Polyphenols through Modulation of APC/EPCR/PAR-1 Axis. Blood, 2019, 134, 4996-4996.	1.4	0
311	A Novel Chemical Compound Inhibiting Hematopoietic Cell Kinase (iHCK) Has a Synergic Effect with Azacytidine (Aza) or Cytarabine (Ara-C) for Acute Myeloid Leukemia Treatment. Blood, 2019, 134, 4650-4650.	1.4	0
312	Sickle Cell Disease Patients Have Altered Number and Function of Dendritic Cells. Blood, 2019, 134, 3569-3569.	1.4	0
313	Crizanlizumab Therapy Is Associated with Lower Levels of Circulating Extracellular Vesicles in Sickle Cell Disease Patients. Blood, 2021, 138, 955-955.	1.4	0
314	A Novel WNT5A-Mimicking Peptide Affects Leukemia Cell Survival in the Bone Marrow Microenvironment. Blood, 2021, 138, 2949-2949.	1.4	0
315	Myelodysplastic Syndromes: Have You Seen Your Patient Beyond His Hemoglobin?. Blood, 2021, 138, 4660-4660.	1.4	0
316	Expression of transforming growth factor Î² pathway components in chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Transplant Immunology, 2022, 70, 101514.	1.2	0
317	Platelet Counts and Mean Platelet Volume As Markers of Clinical Severity in Sickle Cell Disease. Blood, 2020, 136, 36-37.	1.4	0
318	Reduction of ARHGAP21 Alters Platelet Biogenesis in Vitro and Accelerates Hemostatic Response In Vivo. Blood, 2020, 136, 13-13.	1.4	0
319	High expression of apoptosis-regulating proteins in Burkitt's lymphomas. Haematologica, 2002, 87, ELT16.	3.5	0